DeepSkin has US clearance. Here’s what that actually means.
The FDA database lists the DEP100 as an aesthetic electrical stimulator. Clearance is specific; it is not a blank cheque for every beauty claim around it.
Original image by Anecdotal
The FDA’s 510(k) database records DeepSkin DEP100 as a transcutaneous electrical stimulator for aesthetic purposes, with a substantially-equivalent decision dated 8 May 2026.
Why this matters
“FDA cleared” describes a specific device, intended use and regulatory route. It should not be stretched into proof for every claim made around a treatment.
What the database confirms
The FDA record identifies the device classification as a transcutaneous electrical stimulator for aesthetic purposes. The 510(k) decision is listed as substantially equivalent, with the application reviewed under the Neurology panel.
That record confirms a regulatory pathway and device identity. It does not by itself tell a consumer how large an aesthetic effect to expect, how results compare with alternatives or whether a particular clinic is using the cleared device as labelled.
How to read aesthetic-device claims
Check the exact device name, cleared indication, treatment protocol, operator qualifications, contraindications and the evidence supporting the promised outcome. “FDA registered,” “FDA cleared” and “FDA approved” are not interchangeable.
Anecdotal links to the regulator’s record so the status can be checked independently rather than relying on a clinic’s summary.
What this is based on
Regulatory status from the FDA 510(k) database. This is not an independent treatment review.
Regulatory action · Independent
Sources
Go straight to the source.
- 01510(k) Premarket Notification K252621regulator
US Food and Drug Administration · 2026-05-08
Stay in the loop.
The treatments & aesthetics stories worth opening, in one weekly email.
We never sell or share your email. Unsubscribe in one click.
Keep reading
More like this.
Europe is opening an earlier route for breakthrough medical devices
A new pilot lets selected high-risk devices get expert scientific input earlier. The wider programme is expected to expand in 2027.
FDA has changed the warning labels on six menopause hormone products
Specific statements about cardiovascular risk, breast cancer and probable dementia have moved out of the most prominent warning box.
The moringa outbreak is over. The recalled powder may still be in cupboards.
The investigation closed at 131 reported cases across 38 states. Because the products last for years, that is not the same as the risk disappearing overnight.